Literature DB >> 2088648

Antibodies to cardiolipin and intermediate filaments: a study of autoimmunity in rheumatoid arthritis.

R Jacobs1, M G Butler, D L Scott.   

Abstract

Autoantibodies to cardiolipin and intermediate filaments have both been reported with increased frequency in rheumatoid arthritis. We evaluated the frequency, pathological significance, and diagnostic relevance of these autoantibodies in a series of 124 patients and controls. We studied 81 patients with rheumatoid arthritis, 23 with osteoarthritis, and 20 normals. Antibodies to cardiolipin were measured by an ELISA method and antibodies to intermediate filaments were measured by indirect immunofluorescence using HEp2 cells. Antibodies to cardiolipin were present in 58% of rheumatoid patients and antibodies to intermediate filaments were present in 55% rheumatoid patients. They were both predominantly of IgM class, and were more frequent than in normal or osteoarthritic controls. Correlating levels of both these autoantibodies to clinical and laboratory measures of disease activity such as Ritchie articular index and C-reactive protein level showed that no consistent relationships existed. They were not related to other auto-antibodies such as rheumatoid factors and anti-nuclear antibodies, nor to each other. These results show that antibodies to cardiolipin and intermediate filaments in rheumatoid arthritis are of no diagnostic value, they are not related to disease activity, and have no relationship to other autoimmune disturbances. We suggest that several pathological mechanisms must be involved in the development of autoantibodies in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088648     DOI: 10.1007/BF02030513

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Quantitation of "acute-phase proteins" postoperatively. Value in detection and monitoring of complications.

Authors:  C L Fischer; C Gill; M G Forrester; R Nakamura
Journal:  Am J Clin Pathol       Date:  1976-11       Impact factor: 2.493

2.  ANTINUCLEAR FACTOR IN RHEUMATOID ARTHRITIS, ITS INCIDENCE AND CLINICAL SIGNIFICANCE.

Authors:  D J WARD; G D JOHNSON; E J HOLBOROW
Journal:  Ann Rheum Dis       Date:  1964-07       Impact factor: 19.103

3.  Autoantibody to "intermediate filament" in infectious mononucleosis.

Authors:  E Linder; P Kurki; L C Andersson
Journal:  Clin Immunol Immunopathol       Date:  1979-12

4.  Hoechst 33258: a fluorescent nuclear counterstain suitable for double-labelling immunofluorescence.

Authors:  D R Bainbridge; M M Macey
Journal:  J Immunol Methods       Date:  1983-08-26       Impact factor: 2.303

5.  Intermediate filaments in synovial lining cells in rheumatoid arthritis and other arthritides are of vimentin type.

Authors:  O A Osung; M Chandra; E J Holborow
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

6.  Binding of C1q and complement activation by vascular endothelium.

Authors:  E Linder
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

7.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

8.  Anticardiolipin antibodies in rheumatoid arthritis.

Authors:  A Keane; R Woods; V Dowding; D Roden; C Barry
Journal:  Br J Rheumatol       Date:  1987-10

9.  Enzyme release from the perfused rat heart. The functions of the cytoskeleton under cell-pathological conditions.

Authors:  F Diederichs; K Mühlhaus; H Wittenberg; I Trautschold
Journal:  J Clin Chem Clin Biochem       Date:  1986-01

10.  Antibodies to cytoplasmic intermediate filaments in rheumatic diseases.

Authors:  P Kurki; T Helve; I Virtanen
Journal:  J Rheumatol       Date:  1983-08       Impact factor: 4.666

View more
  1 in total

Review 1.  The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Louise E Full; Cristina Ruisanchez; Claudia Monaco
Journal:  Arthritis Res Ther       Date:  2009-04-03       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.